VYNE THERAPEUTICS INC.

(VYNE)
  Report
Delayed Nasdaq  -  05/19 04:00:00 pm EDT
0.3995 USD   -0.08%
05/18VYNE Therapeutics to Present at HC Wainwright & Co. Global Investment Conference
AQ
05/17VYNE THERAPEUTICS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
05/17TRANSCRIPT : VYNE Therapeutics Inc. - Special Call
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

VYNE Therapeutics Inc. Announces Board Changes

01/14/2022 | 05:22pm EDT

VYNE Therapeutics Inc. deeply regrets to announced that Mr. Rex Bright passed away on January 11, 2022. Mr. Bright was a director of the company and also served as the Chair of the Company’s Compensation Committee and a member of the Company’s Audit Committee. On January 14, 2022, the Board appointed Patrick LePore to serve as a member of the Company’s Audit Committee and Elisabeth Sandoval to serve as chairperson of the Compensation Committee.


© S&P Capital IQ 2022
Stocks mentioned in the article
ChangeLast1st jan.
ON SEMICONDUCTOR CORPORATION 0.43% 56.07 Delayed Quote.-17.45%
VYNE THERAPEUTICS INC. -0.08% 0.3995 Delayed Quote.-60.83%
All news about VYNE THERAPEUTICS INC.
05/18VYNE Therapeutics to Present at HC Wainwright & Co. Global Investment Conference
AQ
05/17VYNE THERAPEUTICS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form..
AQ
05/17TRANSCRIPT : VYNE Therapeutics Inc. - Special Call
CI
05/12VYNE THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and..
AQ
05/12Earnings Flash (VYNE) VYNE THERAPEUTICS Reports Q1 Loss $-0.14
MT
05/12Earnings Flash (VYNE) VYNE THERAPEUTICS Reports Q1 Revenue $178,000
MT
05/12VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2..
CI
05/12VYNE Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Up..
AQ
05/12NORTH AMERICAN MORNING BRIEFING : Stocks Seen -3-
DJ
05/10VYNE Hosting Key Opinion Leader Event on Novel InhiBET™ BET Inhibitor Platform
AQ
More news
Analyst Recommendations on VYNE THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2022 0,43 M - -
Net income 2022 -37,4 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,68x
Yield 2022 -
Capitalization 23,1 M 23,1 M -
Capi. / Sales 2022 53,4x
Capi. / Sales 2023 5,51x
Nbr of Employees 28
Free-Float 91,0%
Chart VYNE THERAPEUTICS INC.
Duration : Period :
VYNE Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VYNE THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 0,40 $
Average target price 5,80 $
Spread / Average Target 1 352%
EPS Revisions
Managers and Directors
David Domzalski President, Chief Executive Officer & Director
Tyler Zeronda Chief Financial Officer & Treasurer
Iain A. Stuart Chief Scientific Officer
Sharon Barbari Independent Director
Steven L. Basta Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VYNE THERAPEUTICS INC.-60.83%23
JOHNSON & JOHNSON2.59%457 706
PFIZER, INC.-14.23%284 192
ABBVIE INC.12.05%268 106
ROCHE HOLDING AG-16.41%265 188
ELI LILLY AND COMPANY3.64%257 689